The Cardiovascular Drug Marketplace is at a Crossroads
Medmeme, LLC reports on novel drugs with new mechanisms that may bolster the cardiovascular drug marketplace as many older blockbuster drugs go generic.
New York, NY (PRWEB) July 18, 2012
Medmeme, LLC, a global leader in comprehensive, integrated medical and science information database platforms, announces release of the new syndicated TrendsmemeTM Report: Cardiology. Cardiovascular diseases account for roughly 30% of all deaths worldwide, and in the U.S. nearly 600,000 people die of heart disease and stroke each year. The report focuses on three important indications for this therapeutic category — hypertension, congestive heart failure (CHF), and hyperlipidemia — and details the strategies drug companies are evolving to moderate the influence of major patent expirations for drugs that have maintained very profitable blockbuster status for long runs.
Even with the impending hit from generic competition for many drugs, the Medmeme database shows there has been a high level of activity in medical meeting presentations and medical journal articles published on cardiovascular diseases. For example, the report details that between 2009 and 2011 there were more than 6,600 meeting presentations and more than 2,600 articles focusing on hypertension, nearly 5,200 presentations and approximately 2,200 articles on CHF, and approximately 625 presentations and nearly 370 articles on hyperlipidemia. Key related topics highlighted in this information were genetics, quality of life, diabetes, elderly patients, and obesity. The most active companies presenting information were: Novartis, Merck, Pfizer, Abbott, AstraZeneca, and Bristol-Myers Squibb. Other companies active in the therapeutic category discussed in the report are: Actelion, Boehringer Ingelheim, Cardiorentis, Cytokinetics/Amgen, Daiichi-Sankyo, Isis/Genzyme, and Janssen Pharmaceuticals/Bayer.
The report explains how line extensions are now an important option for pharmaceutical companies with successful cardiovascular product portfolios facing patent expiration. Many of these revolve around an originator product and its follow-ons. However, there are also several new drugs with novel mechanisms in late-stage clinical trials for cardiovascular disease, including renin inhibitors for hypertension, CETP inhibitors for hyperlipidemia, and a variety of approaches for acute heart failure (AHF). And success is indicated for companies able to meet the needs of the various subpopulations of patients within this broad therapeutic category, especially through continued development of novel combination, fixed-dose therapies from distinct drug classes.
Medmeme CEO Mahesh Naithani describes a “one-two” punch to health: ”With the worldwide epidemic of obesity or overweight affecting approximately 1.4 billion adults 20 years old and up; and more than 40 million children under the age of five overweight; and with the direct consequences this has on conditions such as hypertension, hyperlipidemia, and diabetes, the future potential threat to life and cost of CV disease is almost beyond estimate. If this combination trend continues, CV will skyrocket over the next several decades. At that point, how much bigger an issue will obesity-related cardiovascular disease treatment be than that of age/genetic-related CV disease? How will the treatment marketplace look different then? The answers must lie with innovative treatments that reach a large population.”
The syndicated TrendsmemeTM Report: Cardiology can be purchased separately, or, along with other MedMeme reports in the new series, at discounted pricing. To learn more, contact Medmeme, or see the website, http://www.medmeme.com/products/syndicated-reports/reports/trendsmeme-reports
Yan Barshay, Executive Vice President
Ray Wright, Vice President, Sales
+ 1 508-278-4595
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/7/prweb9708262.htm